Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic

Publication/Presentation Date

10-26-2022

Abstract

PURPOSE: Patients with progressive or recurrent meningiomas have limited systemic therapy options. Focal adhesion kinase (FAK) inhibition has a synthetic lethal relationship with

PATIENTS AND METHODS: Eligible patients whose tumors screened positively for

RESULTS: Of 322 patients screened for all mutation cohorts of the study, 36 eligible and evaluable patients with

CONCLUSION: GSK2256098 was well tolerated and resulted in an improved PFS6 rate in patients with recurrent or progressive

First Page

2102371

Last Page

2102371

ISSN

1527-7755

Disciplines

Medicine and Health Sciences

PubMedID

36288512

Department(s)

Hematology-Medical Oncology Division

Document Type

Article

Share

COinS